Hofseth BioCare ASA (HOFBF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -102.52 Million NOK | -681.91% |
| 2022 | -13.11 Million NOK | 12.42% |
| 2021 | -14.97 Million NOK | -17.77% |
| 2020 | -12.71 Million NOK | -38.01% |
| 2019 | -9.21 Million NOK | 88.14% |
| 2018 | -77.69 Million NOK | -22.48% |
| 2017 | -63.43 Million NOK | 53.71% |
| 2016 | -137.03 Million NOK | -19.9% |
| 2015 | -114.28 Million NOK | -92.32% |
| 2014 | -59.42 Million NOK | -25.14% |
| 2013 | -47.48 Million NOK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.85 Million USD | 55.86% |
| 2024 Q1 | -2.42 Million USD | 46.82% |
| 2023 Q3 | -2.45 Million USD | -74.84% |
| 2023 FY | -102.52 Million USD | -681.91% |
| 2023 Q1 | -3.48 Million USD | 3.17% |
| 2023 Q2 | -1.4 Million USD | 59.6% |
| 2023 Q4 | -4.83 Million USD | -96.79% |
| 2022 Q3 | -3.04 Million NOK | -12.54% |
| 2022 Q2 | -2.7 Million NOK | 28.89% |
| 2022 FY | -13.11 Million NOK | 12.42% |
| 2022 Q1 | -3.79 Million NOK | -6.75% |
| 2022 Q4 | -3.59 Million NOK | -18.19% |
| 2021 Q4 | -3.55 Million NOK | 15.21% |
| 2021 Q3 | -4.19 Million NOK | -58.63% |
| 2021 FY | -14.97 Million NOK | -17.77% |
| 2021 Q1 | -2.93 Million NOK | 89.91% |
| 2021 Q2 | -2.64 Million NOK | 9.76% |
| 2020 Q4 | -29.05 Million NOK | 0.37% |
| 2020 Q1 | -15.98 Million NOK | 48.77% |
| 2020 FY | -12.71 Million NOK | -38.01% |
| 2020 Q2 | -17.81 Million NOK | -11.45% |
| 2020 Q3 | -29.16 Million NOK | -63.65% |
| 2019 Q4 | -31.21 Million NOK | -117.04% |
| 2019 FY | -9.21 Million NOK | 88.14% |
| 2019 Q3 | -14.38 Million NOK | 1.99% |
| 2019 Q2 | -14.67 Million NOK | 24.0% |
| 2019 Q1 | -19.3 Million NOK | -3.81% |
| 2018 Q3 | -20.23 Million NOK | -10.77% |
| 2018 Q2 | -18.26 Million NOK | 11.3% |
| 2018 Q1 | -20.59 Million NOK | -73.98% |
| 2018 FY | -77.69 Million NOK | -22.48% |
| 2018 Q4 | -18.59 Million NOK | 8.1% |
| 2017 FY | -63.43 Million NOK | 53.71% |
| 2017 Q3 | -11.34 Million NOK | 38.41% |
| 2017 Q1 | 30.39 Million NOK | 217.12% |
| 2017 Q2 | -18.41 Million NOK | -160.58% |
| 2017 Q4 | -11.83 Million NOK | -4.4% |
| 2016 Q4 | -25.95 Million NOK | 43.09% |
| 2016 Q2 | -47.46 Million NOK | -85.78% |
| 2016 Q1 | -25.54 Million NOK | 35.97% |
| 2016 FY | -137.03 Million NOK | -19.9% |
| 2016 Q3 | -45.6 Million NOK | 3.92% |
| 2015 Q4 | -39.89 Million NOK | -153.65% |
| 2015 Q2 | -19.12 Million NOK | -2.82% |
| 2015 Q1 | -18.59 Million NOK | 34.04% |
| 2015 FY | -114.28 Million NOK | -92.32% |
| 2015 Q3 | -15.73 Million NOK | 17.73% |
| 2014 Q1 | -14.03 Million NOK | -24.64% |
| 2014 Q4 | -28.19 Million NOK | -102.94% |
| 2014 Q3 | -13.89 Million NOK | -46.39% |
| 2014 Q2 | -9.49 Million NOK | 32.38% |
| 2014 FY | -59.42 Million NOK | -25.14% |
| 2013 Q4 | -11.26 Million NOK | -63.81% |
| 2013 Q1 | -24.13 Million NOK | -9.66% |
| 2013 Q2 | -13.84 Million NOK | 42.61% |
| 2013 FY | -47.48 Million NOK | 0.0% |
| 2013 Q3 | -6.87 Million NOK | 50.36% |
| 2012 Q3 | -8.43 Million NOK | 30.02% |
| 2012 Q2 | -12.05 Million NOK | 22.47% |
| 2012 Q4 | -22 Million NOK | -160.86% |
| 2012 Q1 | -15.54 Million NOK | -111.72% |
| 2011 Q3 | -6.03 Million NOK | -11.88% |
| 2011 Q2 | -5.39 Million NOK | 2.64% |
| 2011 Q1 | -5.54 Million NOK | 28.63% |
| 2011 Q4 | -7.34 Million NOK | -21.64% |
| 2010 Q4 | -7.76 Million NOK | -471.15% |
| 2010 Q3 | -1.35 Million NOK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | -3136.115% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -10908.289% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -3802.118% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -474.489% |
| GB Sciences, Inc. | -1.42 Million USD | -7117.765% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -2911.149% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -46487.573% |
| Skye Bioscience, Inc. | -13.67 Million USD | -649.931% |
| Zenith Capital Corp. | -8.94 Million USD | -1046.472% |
| Agentix Corp. | -1.37 Million USD | -7374.288% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -1932.498% |
| Biomind Labs Inc. | -1 Million USD | -10055.378% |
| ContraFect Corporation | -56.88 Million USD | -80.226% |
| CSL Limited | 3.7 Billion USD | 102.77% |
| CytoDyn Inc. | -18.05 Million USD | -467.776% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -5399.391% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -26218.505% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -84.71% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -24577.3% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -6574.852% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -14825.249% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 225.262% |
| SQZ Biotechnologies Company | -75.82 Million USD | -35.218% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -5061.343% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -42.826% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -3496.869% |
| Mesoblast Limited | -84.14 Million USD | -21.845% |
| Marizyme, Inc. | -34.08 Million USD | -200.79% |
| Genus plc | 6.4 Million USD | 1702.016% |
| Pharming Group N.V. | -4.87 Million USD | -2001.2% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1127.892% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -7213.1% |
| IMV Inc. | -38.67 Million USD | -165.128% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -3627.19% |
| MultiCell Technologies, Inc. | -722.81 USD | -14184678.849% |
| ONE Bio Corp. | 13.68 Million USD | 849.396% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -73.807% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 2996.299% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -3433.96% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1442.25% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -342211.031% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -546.066% |
| Alpha Cognition Inc. | -9.7 Million USD | -956.39% |
| Enzolytics Inc. | -2.14 Million USD | -4671.454% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 75.878% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -9720.785% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -3411.936% |
| Genscript Biotech Corporation | -415.79 Million USD | 75.341% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 2186.123% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -39074.175% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -4075.795% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -59680.348% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -5014.286% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 1152.393% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -2151.046% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -2636.72% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -10319.053% |
| EV Biologics, Inc. | -483.06 Thousand USD | -21124.812% |
| Q BioMed Inc. | -3.44 Million USD | -2875.636% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -8063.137% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -86.51% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | -1218.028% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -5205.209% |
| HST Global, Inc. | -140.9 Thousand USD | -72663.596% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7577.596% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -9014.45% |
| Halberd Corporation | -75.05 Thousand USD | -136514.257% |
| Resverlogix Corp. | -12.74 Million USD | -704.212% |
| Cell Source, Inc. | -4.32 Million USD | -2270.423% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -6391.827% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1631.912% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -588436.823% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -4056.424% |
| Kadimastem Ltd | -3.04 Million USD | -3272.387% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -2319.042% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -56394.476% |
| LadRx Corporation | -3.82 Million USD | -2581.46% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -14825.249% |
| Affymax, Inc. | -15.04 Million USD | -581.437% |
| Itoco Inc. | -919.14 Thousand USD | -11054.884% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -9062.556% |
| Mobile Lads Corp. | -554.55 Thousand USD | -18388.685% |
| International Stem Cell Corporation | -663 Thousand USD | -15364.404% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -2583.902% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -407246.047% |
| Qrons Inc. | -643.67 Thousand USD | -15828.641% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -18055.627% |
| SYBLEU INC | -149.18 Thousand USD | -68628.382% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -4497.962% |
| Rebus Holdings, Inc. | -664 Thousand USD | -15341.114% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -5544.875% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -194673.936% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -503975.713% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -182.714% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -6236.774% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -13833.694% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -3195.693% |
| Neutra Corp. | -229.48 Thousand USD | -44577.671% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -484.577% |
| PureTech Health plc | -146.19 Million USD | 29.87% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -377.076% |
| IXICO plc | -1.43 Million USD | -7034.934% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -980.276% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 15.826% |
| CSL Limited | 3.81 Billion USD | 102.69% |
| Cellectis S.A. | -108.85 Million USD | 5.813% |